Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBLG NASDAQ:NDRA NASDAQ:QNRX NASDAQ:STSS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBLGBone Biologics$2.73-2.5%$4.06$2.65▼$18.30$1.53M0.6675,182 shs27,934 shsNDRAENDRA Life Sciences$4.84-8.3%$4.75$2.90▼$143.50$3.97M-0.184.98 million shs26,967 shsQNRXQuoin Pharmaceuticals$6.66-0.6%$8.69$5.01▼$54.95$3.94M1.444,032 shs3,184 shsSTSSSharps Technology$4.83+1.0%$5.43$3.36▼$2,145.00$4.89M2.1542,707 shs38,529 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBLGBone Biologics-2.50%-9.60%-24.59%-37.02%-78.94%NDRAENDRA Life Sciences-8.33%-26.67%+34.44%-21.17%-99.93%QNRXQuoin Pharmaceuticals-0.60%-19.86%-27.53%+9.18%-68.31%STSSSharps Technology+1.05%-21.08%-15.26%+1.68%+482,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBBLGBone Biologics0.7796 of 5 stars0.05.00.00.00.00.01.3NDRAENDRA Life Sciences1.4186 of 5 stars3.52.00.00.00.60.00.6QNRXQuoin Pharmaceuticals1.6887 of 5 stars0.05.00.00.02.40.81.3STSSSharps Technology0.8015 of 5 stars0.04.00.00.00.71.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBLGBone Biologics 0.00N/AN/AN/ANDRAENDRA Life Sciences 3.00Buy$50.00933.06% UpsideQNRXQuoin Pharmaceuticals 0.00N/AN/AN/ASTSSSharps Technology 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBLGBone BiologicsN/AN/AN/AN/A$8.39 per shareN/ANDRAENDRA Life SciencesN/AN/AN/AN/A$4.77 per shareN/AQNRXQuoin PharmaceuticalsN/AN/AN/AN/A$35.47 per shareN/ASTSSSharps TechnologyN/AN/AN/AN/A$110.01 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBLGBone Biologics-$4.11MN/A0.00N/AN/AN/A-130.21%-119.39%8/8/2025 (Estimated)NDRAENDRA Life Sciences-$11.51M-$172.04N/AN/AN/AN/A-140.96%-106.14%8/13/2025 (Estimated)QNRXQuoin Pharmaceuticals-$8.96M-$48.81N/AN/AN/AN/A-148.97%-77.23%8/7/2025 (Estimated)STSSSharps Technology-$9.30M-$1,881.93N/A∞N/AN/A-98.77%-53.85%N/ALatest BBLG, STSS, QNRX, and NDRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025NDRAENDRA Life Sciences-$2.27N/AN/AN/AN/AN/A8/8/2025N/ABBLGBone Biologics-$1.93N/AN/AN/AN/AN/A8/7/2025Q2 2025QNRXQuoin Pharmaceuticals-$6.83N/AN/AN/AN/AN/A5/15/2025Q1 2025STSSSharps TechnologyN/A$38.62N/A$38.62N/AN/A5/13/2025Q1 2025QNRXQuoin Pharmaceuticals-$3.85-$6.50-$2.65-$6.50N/AN/A5/12/2025Q1 2025BBLGBone Biologics-$2.88-$1.92+$0.96-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBLGBone BiologicsN/AN/AN/AN/AN/ANDRAENDRA Life SciencesN/AN/AN/AN/AN/AQNRXQuoin PharmaceuticalsN/AN/AN/AN/AN/ASTSSSharps TechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBLGBone BiologicsN/A12.6012.60NDRAENDRA Life SciencesN/A3.853.85QNRXQuoin PharmaceuticalsN/A2.572.57STSSSharps TechnologyN/A1.651.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBLGBone Biologics34.30%NDRAENDRA Life Sciences1.19%QNRXQuoin Pharmaceuticals8.63%STSSSharps Technology17.17%Insider OwnershipCompanyInsider OwnershipBBLGBone Biologics6.10%NDRAENDRA Life Sciences0.04%QNRXQuoin Pharmaceuticals13.46%STSSSharps Technology1.46%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBLGBone Biologics2550,000512,000Not OptionableNDRAENDRA Life Sciences20750,000753,000Not OptionableQNRXQuoin Pharmaceuticals4590,000509,000Not OptionableSTSSSharps Technology31.02 million1.01 millionNot OptionableBBLG, STSS, NDRA, and QNRX HeadlinesRecent News About These CompaniesSharps Technology (NASDAQ:STSS) vs. Haleon (NYSE:HLN) Critical AnalysisJuly 30 at 3:25 AM | americanbankingnews.comSharps Technology Inc. Stock Grades | STSS | Barron'sJuly 17, 2025 | barrons.comSharps Technology Appoints Paul Danner as Executive ChairmanJuly 9, 2025 | theglobeandmail.comSharps Technology Inc. Company & People | STSS | Barron'sJune 29, 2025 | barrons.comSharps Technology Inc News (STSS) - Investing.comJune 26, 2025 | investing.comSharps Technology Advances Shipment Under $50 Million SoloGard Supply Agreement and Begins Manufacturing Facility UpgradesJune 18, 2025 | globenewswire.comSharps Technology CEO, Robert Hayes, to Present at the Life Sciences Virtual Investor Forum on June 12 at 9:30AM ETJune 11, 2025 | markets.businessinsider.comSharps Technology CEO, Robert Hayes, to Present at the Life Sciences Virtual Investor Forum on June 12 at 9:30AM ETJune 11, 2025 | financialpost.comFSharps Technology CEO, Robert Hayes, to Present at the Life Sciences Virtual Investor Forum on June 12 at 9:30AM ETJune 11, 2025 | globenewswire.comSharps Technology CEO, Robert Hayes, to Present at the Life Sciences Virtual Investor Forum on June 12 at 9:30AM ETJune 10, 2025 | financialpost.comFSharps Technology CEO, Robert Hayes, to Present at the Life Sciences Virtual Investor Forum on June 12 at 9:30AM ETJune 10, 2025 | globenewswire.comSharps Technology, Inc. CEO Robert Hayes to Present at Virtual Investor Summit on June 10, 2025June 9, 2025 | quiverquant.comQSharps Technology CEO, Robert Hayes, to Present at the Virtual Investor Summit on June 10, 2025June 9, 2025 | globenewswire.comSharps Technology stock soars on first commercial shipmentsJune 4, 2025 | investing.comSharps Technology Shares Rise After New Shipments BeginJune 4, 2025 | marketwatch.comSharps Technology Begins Shipping Smart Safety SyringesJune 4, 2025 | tipranks.comSharps Technology, Inc. Begins Commercial Shipments of Smart Safety Syringes, Marking Revenue Generation MilestoneJune 4, 2025 | quiverquant.comQSharps Technology Begins Shipments Across Three Customer Orders Under Previously Announced Purchase AgreementsJune 4, 2025 | globenewswire.comSharps Technology Regains Nasdaq ComplianceMay 22, 2025 | tipranks.comSharps Technology Regains Compliance with Nasdaq Minimum Bid Price Listing RuleMay 22, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBBLG, STSS, NDRA, and QNRX Company DescriptionsBone Biologics NASDAQ:BBLG$2.73 -0.07 (-2.50%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.73 0.00 (0.00%) As of 08/1/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.ENDRA Life Sciences NASDAQ:NDRA$4.84 -0.44 (-8.33%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.84 0.00 (-0.10%) As of 08/1/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.Quoin Pharmaceuticals NASDAQ:QNRX$6.66 -0.04 (-0.60%) Closing price 08/1/2025 03:56 PM EasternExtended Trading$6.66 0.00 (0.00%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.Sharps Technology NASDAQ:STSS$4.83 +0.05 (+1.05%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.80 -0.03 (-0.62%) As of 08/1/2025 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sharps Technology, Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. Sharps Technology, Inc. was incorporated in 2017 and is based in Melville, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
